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Inflammatory diseases are a major socio-economic burden, with the incidence of such conditions on the rise, especially in western
societies. For decades, the primary treatment paradigm for many of these conditions was to develop drugs that inhibit or
antagonize the production and biological actions of molecules that were thought to be the culprits in propagating disease; these
include cytokines and eicosanoids. This approach is effective in controlling disease propagation; however, long-term exposure to
these anti-inflammatories is also associated with many side effects, some of which are severe, including immune-suppression. The
discovery that termination of self-limited acute inflammation is an active process orchestrated by endogenous mediators,
including the essential fatty acid-derived resolvins, protectins and maresins, has provided novel opportunities for the design of
therapeutics that control inflammation with a lower burden of side effects. This is because at variance to anti-inflammatories, pro-
resolving mediators do not completely inhibit inflammatory responses; instead, these mediators reprogramme the immune
response to accelerate the termination of inflammation, facilitating the regain of function. The scope of this review is to highlight
the biological actions of these autacoids and their potential utility as lead compounds in developing resolution pharmacology-
based therapeutics.
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During evolution, multicellular organisms arose and cells
within an organism became specialized to perform specific
tasks leading to the formation of organs and tissues. These
specialized organs required protection from invading
microbes as well as mechanisms to repair and regenerate
damaged tissues and organs, thus paving the way to the evo-
lution of the immune system (Malagoli, 2016). In higher
organisms, the immune system is divided into two arms, the
innate arm provides the front line defence system and the
adaptive arm provides protection from insults and/or patho-
gens to which the body was previously exposed. In some
instances, immune responses may become dysregulated
leading to disease. It is now appreciated that a significant por-
tion of diseases that afflict western societies are associated
with unbridled inflammation leading to damage of vital
organs and tissues resulting in malaise and ultimately death
(Kumar et al., 2014; Majno, 1991).
Classically, the inflammatory response has been divided
into two phases, the initiation and resolution (or termina-
tion) phases (Kumar et al., 2014). Many studies conducted
primarily in the last century focused on determining the
mechanisms and molecules produced during the initiation
phase, demonstrating that this was a tightly orchestrated
response with the production of several classes of molecules
that are involved in the recruitment of different leukocyte
subsets and include the cytokines, chemokines and the
classic eicosanoids (Kumar et al., 2014). Interested readers
on the biology of these mediators are directed to articles in
this special edition as well as to Samuelsson (2012) and
Dinarello and Joosten (2016). The identification of these
molecules also paved the way to the development of
innovative therapeutics for the treatment of many inflamma-
tory diseases that revolutionized medicine and medical
practice. The drugs were designed to inhibit or antagonize
the biological actions and the production of local mediators
that were identified to be important in disease onset and
progression. Longitudinal studies on the use of many of these
therapeutics demonstrate that while these molecules are
effective at inhibiting inflammation, they also come
with many side effects. For example, non-steroidal anti-
inflammatory drugs (NSAIDs) lead to an increased incidence
of gastrointestinal bleeds (Goldstein and Cryer, 2015), and
anti-TNF increase the incidence of infections (Minozzi et al.,
2016). Thus, these observations underscore an urgent need
for the development of alternative approaches, especially in
the treatment of chronic diseases, which would not interfere
with the immune system and would carry a lower burden of
side effects.
For many years, termination of inflammation was
thought to occur via the simple dilution of inflammatory
signals from the site of injury or infection, leading to the
egress of white blood cells and re-establishment of tissue
function (Robbins and Cotran, 1979). Studies focusing on
mechanisms that control the termination of inflammation
demonstrated that arachidonic acid is not only a substrate
in the biosynthesis of inflammation-initiating molecules,
such as PGs and leukotrienes, but is converted to protective
and anti-inflammatory molecules that include the lipoxins
(Serhan et al., 1984; Levy et al., 2001) and the cyclopentenone
PGs (Gilroy et al., 1999). Identification of these molecules
indicated that resolution of inflammation is an active process
coordinated by autacoids produced at the site that control
immune cell responses. Introducing quantitation indices
to mark resolution permitted the delineation of the
in vivo biological actions of pro-resolving mediators, includ-
ing the lipoxins, resolvins and protectins, during acute in-
flammation (Bannenberg et al., 2005; Schwab et al., 2007).
Detailed studies investigating mechanisms controlling the
termination of inflammation also uncovered a link be-
tween the inflammation-initiating eicosanoids PGE2 and
PGD2 and lipoxin biosynthesis. These PGs are important
in up-regulating the expression of 15-lipoxygenase type 1
(15-LOX-1), the initiating enzyme in the lipoxin biosyn-
thetic pathway (Levy et al., 2001). Of note, inhibition of
PG biosynthesis using NSAIDs is linked to a reduction in
the biosynthesis of specialized pro-resolving mediators
and a delay in the termination of inflammation in experi-
mental systems (Fukunaga et al., 2005). Thus, these studies
demonstrated that the acute inflammatory response is a
coordinated process with the initiation and termination
phases being intricately linked.
These initial observations also raised the question
whether novel molecules are produced during acute inflam-
mation to promote its termination and activate reparative
and regenerative responses thereby paving the way to the
re-establishment of tissue and organ function. Using a
systems approach, we uncovered three novel mediator
superfamilies that actively reprogramme the host immune
response to halt inflammation and re-establish organ
function (Serhan et al., 2000; 2002; 2009; Dalli et al., 2013;
2014; 2015a). Given their potent biological actions, these
mediators were termed as specialized pro-resolving mediators
(SPM). This superfamily is composed of mediators that are
produced via the stereoselective conversion of essential fatty
acids and include the docosahexaenoic acid derived resolvins
(RvD), protectins andmaresins and the eicosapentaenoic acid
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derived resolvins (RvE) (Serhan et al., 2017). The production
of these mediators is regulated in a time, organ and
stimulus-dependent manner (see Dalli, 2017), and their
relative concentrations to classic eicosanoids are also
dependent on these factors. For example, in cerebrospinal
fluids from patients with multiple sclerosis PGE2 and
RvD1 concentrations were present at similar concentrations
(~1 pg·mL1) (Pruss et al., 2013). In experimental models of
eye infections, LXA4 concentrations were between 2- and
10-fold higher than those of PGE2. The production of
eicosanoids and SPM is also regulated in a sex-dependent
manner where LXA4 concentrations in females were elevated
when compared to males during experimental eye
infections (Livne-Bar et al., 2017), whereas RvD and RvE are
elevated during experimental inflammation in humans
(Rathod et al., 2017). The scope of the present review is to
discuss the evidence underpinning the protective actions
of SPM and how insights into their biological actions may
provide leads on the utility of harnessing SPM as
templates for the development of resolution pharmacology-
based therapeutics that would carry a lower burden of
side effects.
The identification and structure
elucidation of novel immunoresolvents
The EPA bioactive metabolome
In order to establish whether novel molecules are produced
during the resolution phase that actively promote the termi-
nation of inflammation, it is essential to employ a systems
approach. For this purpose, we developed metrics to measure
the kinetics of cellular trafficking as well as tissue regenera-
tion responses (Bannenberg et al., 2005; Schwab et al.,
2007). Using this approach, we found that during acute,
self-limited inflammation, eicosapentaenoic acid (EPA)
was converted in inflammatory exudates to novel mediators
that potently and stereospecifically promoted the termina-
tion of inflammation and were thus coined as E-series
resolvins (RvE) (Serhan et al., 2000).
Investigations into the mechanisms activated by these
molecules demonstrated that these mediators directly
counter-regulate the production of pro-inflammatory
mediators, including TNF-α and inflammatory eicosanoids.
In addition, the biological actions of RvE1 at controlling
leukocyte responses were found to be more potent than those
of aspirin and dexamethasone. RvE1 was also found to carry
potent antinociceptive actions reducing inflammatory pain
by regulating both central and peripheral responses with
activities of 10 ng per mouse when administered intrathe-
cally and 285–570 pmol when administered peripherally
in vivo. These actions were also displayed in vitro at concentra-
tions as low as 3 nM (Xu et al., 2010; Jo et al., 2016; Fonseca
et al., 2017). Of note, the antinociceptive properties of RvE1
are more potent than those exerted by the COX-2 inhibitor
NS398 and morphine (Xu et al., 2010).
In studies assessing the role of omega-3 supplementation
in patients with arthritis, Barden and colleagues (2016) found
an association between the synovial fluid concentrations of
RvE2 and joint pain, where higher RvE2 concentrations were
associated with lower pain scores in these patients. RvE2 is
also antidepressant; i.c.v. infusions (10 ng per mouse)
reduced LPS-induced depression in mice via the activation
of mTORC1 signalling in the medial prefrontal cortex and
hippocampal dentate gyrus (Deyama et al., 2018). Isobe
and colleagues also found that the RvE1 and RvE2 precursor
18-hydroxy-eicosapentaenoic acid is converted by eosino-
phils to a novel bioactive mediator denoted as RvE3. This
mediator, at 10–100 ng per mouse, displays potent anti-
inflammatory properties characteristic of the SPM family,
including the ability to regulate neutrophil recruitment
(Isobe et al., 2012; Isobe et al., 2013).
The DHA bioactive metabolome – protectins
EPA is not the only omega-3 essential fatty acid that is converted
during acute self-limited inflammation to novel bioactivemedi-
ators. Docosahexaneoic acid is also a substrate for the formation
of two SPM families produced via a key 17-hydroperoxy-
docosahexaenoic acid intermediate and coined as D-series
resolvins and protectins (Serhan et al., 2017). In peripheral tis-
sues, these mediators are produced by leukocytes and their bio-
synthesis is temporally regulated (Dalli et al., 2013a; Winkler
et al., 2016). In neural tissues, the protectin biosynthetic path-
way regulates both stromal and immune cell responses. In reti-
nal pigmented cells, protectin D1 (PD1; 50 nM; referred to as
NPD1 in neuronal systems) potently counteracts H2O2/TNF-α
oxidative-stress-triggered DNA damage. PD1 also up-regulates
the expression of several anti-apoptotic proteins including
Bcl-2 and Bcl-xL and decreases the expression of the pro-
apoptotic factors Bax and Bad as well as the executioner cas-
pase, caspase 3 (Mukherjee et al., 2004). In cytokine-stressed
human neural cells, PD1 formation was associated with an
attenuation of amyloid-β secretion (Lukiw et al., 2005). This
SPM was also reduced in the hippocampal cornu ammonis
region 1 from patients with Alzheimer’s disease but not in the
thalamus or occipital lobes from the same brains. Furthermore,
the expression of key enzymes in the biosynthesis of PD1, cyto-
solic PLA2 and 15-LOX, was altered in the hippocampus of pa-
tients with Alzheimer’s disease (Lukiw et al., 2005). NPD1 at
300 ngper eye also reduces the severity and incidence of stromal
keratitis and corneal neovascularization following herpes sim-
plex virus infections (Rajasagi et al., 2013).
Recent studies have implicated a subset of eosinophils in
the biosynthesis of PD1 during the course of self-limited in-
flammation. Eosinophil recruitment to inflamed loci during
the resolution phase of acute inflammation correlates with
an increase in PD1 production (~100 pg per exudate; Yamada
et al., 2011). Depletion of eosinophils results in a delay in
resolution responses, including an impairment of lymphatic
drainage with a reduction in the appearance of phagocytes
carrying engulfed zymosan in the draining lymph node and
sustained numbers of polymorphonuclear leukocytes in
inflamed tissues. The resolution deficit caused by eosinophil
depletion was rescued by eosinophil restoration or the ad-
ministration of PD1, 5 μg per mouse (Yamada et al., 2011).
Of note, PD1 production is reduced from 2.23 ± 1.55 ng·mL1
in healthy volunteers to trace concentrations in exhaled
breath from asthmatics (Levy et al., 2007). This reduction in
PD1 biosynthesis is also observed in isolated eosinophils
from patients with severe asthma, suggesting a role for
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defective production of this SPM in disease onset and/or
propagation (Miyata et al., 2013).
The DHA bioactive metabolome – resolvins
The D-series resolvins are now thought to regulate host
immune responses in a number of disease settings. In Pseudo-
monas aeruginosa-mediated lung infection RvD1, at 100 ng
per mouse, significantly reduces P. aeruginosa titres, leukocyte
infiltration and lung tissue damage (Codagnone et al., 2018).
In murine lung macrophages sorted during P. aeruginosa
chronic infection, RvD1 regulates the expression of Toll-like
receptors (TLRs), downstream genes, as well as microRNA
(miR)-21 and 155, resulting in a reduction in inflammatory
signalling. In vitro, RvD1 up-regulates P. aeruginosa
phagocytosis by both neutrophils and macrophages
(Codagnone et al., 2018).
RvD2 was recently identified in skeletal muscle biopsies
from humans with peripheral artery disease at concentra-
tions of ~150 pg·g1 of tissue. When this mediator was ad-
ministered to mice (100 ng per mouse) during ischaemia/
reperfusion, it enhanced perfusion recovery and promoted
arteriogenesis (Zhang et al., 2016). In contrast to other strate-
gies used for revascularization that exacerbate inflammation,
RvD2 does not enhance vascular permeability, it reduces
neutrophil accumulation in the damaged tissues and plasma
inflammatory cytokine levels, including TNF-α and granulo-
cyte macrophage colony-stimulating factor. RvD2 also in-
creases myocyte regeneration, enhances endothelial cell
migration in a Rac-dependent manner and restores defective
revascularization in diabetic mice (Zhang et al., 2016). In
alipoliprotein E (ApoE) deficient mice, RvD2 concentrations
also correlated with the signs of plaque stability, and an
injection of RvD2 (100 ng per mouse) to ApoE/ mice
prevented atheroprogression, reduced macrophage recruit-
ment, increased fibrous cap thickness and smoothmuscle cell
numbers (Viola et al., 2016).
Additionally, RvD3 displays potent tissue protective
actions. RvD3 was identified in uninjured lungs, suggesting
that it plays a functional role in regulating tissue resolution
tone (Colby et al., 2016). The concentrations of this
mediator are rapidly up-regulated following hydrochloric
acid-initiated injury from ~22 to ~75 pg per lung. Administra-
tion of the metabolically stable endogenous isomer of RvD3,
17R-RvD3 (10 ng per mouse), affords significant tissue protec-
tion during hydrochloric acid-initiated injury, reducing alve-
olar wall thickening, lung oedema and leukocyte infiltration
(Colby et al., 2016). This mediator also increases lung
epithelial cell proliferation, bronchoalveolar lavage fluid
levels and keratinocyte growth factor promoting cutaneous
re-epithelialization (Colby et al., 2016).
In murine tissues infected with Staphylococcus aureus,
recent studies found that RvD4 persists late into the resolu-
tion phase at concentrations of 0.75 pg per exudate (Winkler
et al., 2016). Administration of this mediator (200 ng per
mouse) during S. aureus infection reduces neutrophilic
infiltration, increases bacterial clearance and restores resolu-
tion responses. RvD4 also enhanced the uptake of apoptotic
neutrophils by human dermal fibroblasts at concentrations
as low as 0.1 nM (Winkler et al., 2016). RvD5 displays potent
anti-bacterial actions, up-regulating neutrophil and macro-
phage phagocytosis of bacteria in a dose- and receptor-
dependent manner (Chiang et al., 2012). Of note, RvD
biosynthesis in tissues is regulated in both a stimulus- and
tissue-dependent manner, thereby demonstrating that these
mediators exert distinct biological actions during self-limited
inflammation (Figure 1) (Chiang et al., 2012; Dalli et al.,
2013a; Winkler et al., 2016).
The DHA bioactive metabolome – maresins
Macrophages are central players in regulating the host
immune response. We recently found that these cells also
produce a novel family of mediators termedmaresins (macro-
phage mediators in resolving inflammation) (Serhan et al.,
2009). The biosynthesis of this family of mediators is initi-
ated by lipoxygenation and subsequent epoxidation of DHA
to yield 13S,14S-epoxy-MaR (13S,14S-eMaR). This product
regulates the production of the leukocyte chemoattractant
LTB4 via the direct inactivation of the LTA4 hydrolase (Dalli
et al., 2013b). 13S,14S-eMaR (10 nM) also increases the ex-
pression of markers associated with an alternatively activated
phenotype in human macrophages, including CD163 and
CD206, and down-regulating the expression of markers
linked with a classically activated phenotype including
CD54 (Dalli et al., 2013b). In addition to directly regulating
aspects of the immune response, 13S,14S-eMaR is also con-
verted to MaR1 and MaR2 via enzyme-mediated hydrolysis
(Serhan et al., 2009; Dalli et al., 2013b; Deng et al., 2014).
MaR1, the first member of this family identified, is
antinociceptive regulating the activation of TRPV1 by capsai-
cin at concentrations as low as 0.5 ng·mL1. Administration of
MaR1 at 10 ng per mouse also inhibits chemotherapy-elicited
neuropathic pain (Serhan et al., 2012). MaR1 exerts protective
actions on hepatocytes, reducing lipotoxicity-induced apopto-
sis by activating the unfolded protein response pro-survival
mechanisms and limiting the up-regulation of pro-apoptotic
pathways (Rius et al., 2017). This macrophage-derived mediator
regulates the expression of miRNA targeting both protein fold-
ing and apoptosis and enhances the phagocytic capacity of
Kupffer cells (Rius et al., 2017).
Recent studies also demonstrate that MaR1 is produced by
circulating neutrophil–platelet aggregates. During these het-
erotypic cell aggregates, DHA is converted to 13S,14S-eMaR
by the platelet 12-LOX. This intermediate is then donated
to neutrophils that, via enzyme-mediated hydrolysis, pro-
duce MaR1 (Abdulnour et al., 2014). The production of
MaR1 by these heterotypic cell aggregates in the vasculature
is a protective mechanism engaged to limit tissue damage fol-
lowing acid-induced lung injury and results in a reduction of
activated neutrophil recruitment into the damaged tissues
(Abdulnour et al., 2014). At the site of infectious inflamma-
tion, MaR1 is subjected to further metabolism by exudate leu-
kocytes. Macrophages convert this mediator to 14-oxo-MaR1,
which displays blunted biological actions in comparison to
the parent mediator. Neutrophils convert MaR1 to 22-OH-
MaR1 that retains the potent biological actions of the parent
SPM, including its ability to regulate the activation of the
LTB4 receptor (BLT1 receptor) by its cognate ligand (Colas
et al., 2016). In the CNS, MaR1 also displays reparative ac-
tions, where MaR1 (1 μg per mouse, i.v.) administration to an-
imals subjected to spinal cord injury improved locomotor
recovery and reduced secondary injury progression
(Francos-Quijorna et al., 2017).
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The DHA bioactive metabolome – sulfido
conjugated SPM
In recent studies, we found that 13S,14S-eMaR is also an
intermediate in the biosynthesis of a novel family of peptide-
lipid conjugated molecules termedmaresin conjugates in tissue
regeneration (MCTR) (Dalli et al., 2014). This family of media-
tors is evolutionary conserved being identified in planaria, mice
and humans. Furthermore, in each of these species, MCTR dis-
plays potent tissue protective and tissue regenerative actions.
During murine infections, MCTRs are produced late within the
Figure 1
Temporal, tissue and stimulus specific SPM regulation during sterile and infectious inflammation. (A) Mice were challenged with 1 μg of zymosan;
inflammatory exudates were collected at the indicated intervals and lipid mediators quantified as in Dalli et al. (2013a). Results were analysed
using multivariate analysis. (A, left panel) Depicts the temporal shift in lipid mediator clusters during the course of initiation and resolution.
(A, right panel) Denotes the contribution of each mediator to the temporal clustering. (B, top panel) Mice were challenged and lipid mediators
were identified and quantified. Panels are illustrations of results presented in Dalli et al. (2013a). (B; bottom panel) Mice were challenged with
Staphylococcus aureus and lipid mediators identified and quantified. Panels are illustrations of results presented in Winkler et al. (2016).
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resolution phase, coinciding with the turning on of reparative
and regenerative responses (Dalli et al., 2014). Administration
of MCTRs (100 nM) to planaria following surgical injury leads
to the up-regulation of genes involved in tissue regeneration.
In mice following ischaemia–reperfusion mediated injury,
MCTR1 and MCTR2 (50 ng per mouse each) up-regulate the ex-
pression of proteins involved in lung repair and regeneration,
including Ki67 and R-spondin 3 (Dalli et al., 2014). Identifica-
tion of the MCTRs also paved the way to the identification of
two novel peptide lipid conjugated mediator families termed
as protectin conjugates in tissue regeneration (PCTR) and
resolvin conjugates in tissue regeneration (RCTR) (Dalli et al.,
2015b). These mediators display tissue regenerative and leuko-
cyte directed actions controlling a host’s response to the Gram-
negative bacterium Escherichia coli (Dalli et al., 2015b). PCTR1
production in the murine peritoneum is under neural control
(Dalli et al., 2017). This mediator is central inmaintaining tissue
resolution tone via regulating tissue resident macrophage phe-
notype and function. Disruption of the vagus nerve or
inhibiting 15-LOX, the initiating enzyme in the PCTR
biosynthetic pathway, perturbs PCTR production leading to im-
paired host responses to E. coli infections, including delayed res-
olution of self-limited inflammation and a reduction in the
ability of recruited leukocytes to phagocytose and kill bacteria
(Dalli et al., 2017).
The n-3 docosapentaenoic acid bioactive
metabolome
We recently found that n-3 docosapentaenoic acid (DPA) was
not simply a precursor in the biosynthesis of DHA from EPA.
This essential fatty acid is converted by leukocytes to
several mediator families that are congeners to those pro-
duced when DHA is the substrate (Figure 2) (Dalli et al.,
2013). In murine plasma and inflammatory exudates
following ischaemia–reperfusion injury, we found that n-3
DPA is converted to the D-series resolvins, RvD1n-3 DPA,
RvD2n-3 DPA and RvD5n-3 DPA as well as PD1n-3 DPA with con-
centrations at the site of inflammation for these SPM ranging
between 20 and 100 pg per exudate (Dalli et al., 2013). These
new mediators each display potent leukocyte-directed
properties, reducing neutrophil recruitment during acute
peritonitis and leukocyte-mediated lung damage during
ischaemia–reperfusion (Dalli et al., 2013; Aursnes et al.,
2014). Human leukocytes, in addition to producing RvDn-3
DPA and PDn-3 DPA, also convert n-3 DPA to MaRn-3 DPA, which
displays leukocyte and endothelial directed actions reducing
the expression of CD54 in TNF-α activated endothelial cells
(Dalli et al., 2013; Tungen et al., 2014). The biosynthesis of
RvD5n-3 DPA and PD1n-3 DPA is disrupted in colonic biopsies
from patients with inflammatory bowel disease as well as in
mice given dextran sodium sulphate (DSS) (Gobbetti et al.,
2017). Administration of either of these mediators provided
significant protection against DSS-initiated colon inflamma-
tion. Furthermore, increasing the endogenous production of
these mediators in mice during DSS-initiated colitis also led
to a significant reduction in tissue damage (Gobbetti et al.,
2017). In this context, recent studies in healthy volunteers
found that supplementation with n-3 DPA increased plasma
RvD5n-3 DPA concentrations (Markworth et al., 2016). Using
a lipidmediator profiling approach, we found that in humans
systemic concentrations of RvDn-3 DPA diurnally regulated
Figure 2
Novel immunoresolvents biosynthesized from n-3 docosapentaenoic. In the vasculature, n-3 docosapentaenoic acid is the substrate for conver-
sion, by endothelial COX-2, to 13-HDPA that is then donated to neutrophils and converted to RvT that display potent protective actions in infec-
tious inflammation (Dalli et al., 2015a). The n-3 docosapentaenoic is also converted by leukocytes to 17-HpDHA that is a precursor to RvDn-3 DPA
and PDn-3 DPA. Conversion of n-3 DPA via 14-lipoxygenation yields 14-HpDPA that is converted to MaRn-3 DPA. Each of these mediator families dis-
plays potent leukocyte-directed and host-protective actions (Dalli et al., 2013; Gobbetti et al., 2017).
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and their concentrations correlate with markers of both
platelet and leukocyte activation including CD11b and
CD62P (Colas et al., 2018).
In the vasculature during ongoing inflammation, n-3 DPA
is also converted to the 13-series resolvins (RvT) (Dalli et al.,
2015a). The biosynthesis of these mediators is initiated by
endothelial COX-2 that converts the essential fatty acid to
13-(R)-hydroxyperoxy-7Z,10Z,13R,14E,16Z,19Z-docosapent-
aenoic acid (13-HpDPA). This or its reduced form, namely,
13-HDPA, are then donated to neutrophils for transcellular
biosynthesis to produce RvT (Dalli et al., 2015a; Primdahl
et al., 2016). These mediators are produced during the early
stages of self-limited bacterial infections with plasma
concentrations reaching concentrations of ~30–50 pg·mL1.
These mediators regulate the ability of leukocytes to uptake
and kill bacteria. RvT also down-regulate the activation of
the NACHT, LRR and PYD domain-containing protein 3
(NALP3) inflammasome in murine and human macro-
phages, reducing the expression of caspase 1 and the
production of IL-1β as well as the release of LDH, a hallmark
of pyroptosis (Dalli et al., 2015a). In addition, RvTs are also
important in mediating the biological actions of atorvastatin
and pravastatin (Dalli et al., 2015a; Walker et al., 2017). Ad-
ministration of these statins regulates COX-2 activity by
up-regulating the NOS-mediated nitrosylation of the en-
zyme, increasing its catalytic turnover and 13-HDPA forma-
tion (Dalli et al., 2015a). Inhibition of either NOS or COX-
2 using specific pharmacological inhibitors led to a reversal
of the protective actions of atorvastatin and pravastatin in
both infectious inflammation and rheumatoid arthritis
(Dalli et al., 2015a; Walker et al., 2017).
How do the SPM exert their biological
actions?
Agonists of GPCRs
The biological actions of SPM are stereoselective and are medi-
ated via the activation of cognate receptors and signalling path-
ways. The first of these receptors to be identified was the LXA4
receptor, whichupuntil thenwas thought to be a low affinity re-
ceptor for endogenous formylated peptides (Fiore et al., 1994).
The LXA4 receptor (ALX) is part of the GPCR family (Figure 3).
Its activation by cognate endogenous ligands, including LXA4
and the pro-resolving protein annexin A1, displays a charac-
teristic bell shape,where at either end of the dose range, the abil-
ity of the ligand to activate the receptor is significantly reduced
(Hayhoe et al., 2006; Rovira et al., 2010). Of note, ALX receptor
activation by its pro-resolving ligands leads to distinct down-
stream signalling pathways that are cell specific. For example,
LXA4 increases intracellular calcium levels in conjunctival gob-
let cells via the ALX receptor (Hodges et al., 2016); whereas
activation of this receptor by LXA4 does not elicit a calcium re-
sponse in human neutrophils (Fiore and Serhan, 1995). Studies
conducted by Cooray and colleagues demonstrate that the ALX
receptor on cell membranes is expressed as a homo- or heterodi-
mer with the formyl peptide receptor FPR1 or FPR3 (the two
other family members) and operates in a ligand-biased fashion.
Furthermore, signalling pathways activated by these different
dimerization states are distinct (Cooray et al., 2013). This process
of dimerization is at least in part influenced by the ligands them-
selves whereby annexin A1 promotes homodimerization and
the activation of p38/MAPK-activated protein kinase/heat
shock protein 27 signalling and IL-10 up-regulation (Cooray
et al., 2013). On the other hand, the pro-inflammatory acute
phase protein serum amyloid protein A did not lead to receptor
homodimerization. These findings shed light onhowone recep-
tor can mediate the biological actions of functionally distinct
molecules (Cooray et al., 2013). In addition to mediating the bi-
ological actions of LXA4 and its aspirin triggered epimer (Ortiz-
Munoz et al., 2014; Wang et al., 2014; Romano et al., 2015),
the ALX receptor also mediates the actions of the D-series
resolvins RvD1, RvD3 and their aspiring trigger epimers
(Krishnamoorthy et al., 2012; Arnardottiret al., 2016; deOliveira
et al., 2017; Mottola et al., 2017; Serhan et al., 2017).
Activation of the orphan receptor GPR32 by RvD1
leads to the regulation of a number of miRNA involved in
the orchestration of acute inflammation, including miR-
146b, miR-208a and miR-219 (Krishnamoorthy et al.,
2012; Serhan et al., 2017). This receptor also mediates the
biological actions of RvD5 in the context of bacterial infec-
tions, whereby its activation by RvD5 leads to enhanced
bacterial phagocytosis in human macrophages and a
down-regulation of several pro-inflammatory genes, includ-
ing NF-κB and TNF-α (Chiang et al., 2012). In lung cancer
cells, GPR32 also mediates the biological actions of RvD1
in preventing TGFβ1-induced epithelial-mesenchymal-
transition (Lee et al., 2013). Additionally, this receptor is in-
volved in regulating macrophage phenotype and function,
whereby it mediates RvD1-initiated regulation of pro-
inflammatory cytokines IL-1β and IL-8. GPR32 is also in-
volved in mediating the inhibitory actions of RvD1 on
macrophage chemotaxis towards chemerin, fMLF and
monocyte chemoattractant protein-1 (also known
as CCL2) (Schmid et al., 2016).
The biological actions of the E-series resolvins, RvE1 and
RvE2, are mediated by chemerin receptor 2 /resolvin E1
(chemerin1) receptor (ERV1; Arita et al., 2005; Oh et al.,
2012). RvE1 signalling via the chemerin1 receptor (ERV1)
leads to the activation of PI3K and ERK resulting in the
phosphorylation of both Akt and the ribosomal protein S6
(Arita et al., 2005). The expression of this receptor in human
diabetic patients is up-regulated. Of note, despite increased
expression of the RvE receptor in diabetic neutrophils, the
biological actions of RvE1 in these patients are blunted
suggesting that impaired/defective signalling of this receptor
in diabetes may be a component in the ethiopathogenis of
the disease (Freire et al., 2017). The expression of chemerin1
receptors (ERV1) in human monocyte-derived macrophages
was recently shown to be regulated by LPS and IFN-γ,
where incubation of monocyte-derived macrophages with
these inflammatory signals activates the promoter of these
receptors (Herova et al., 2015).
GPR18 (resolvin D2 receptor; DRV2) is a receptor for
RvD2. The binding of the agonist to its receptor leads to an
increase in intracellular cAMP as well as CREB, ERK1/2 and
STAT3 phosphorylation. Loss of this receptor in transgenic
animals is associated with delayed resolution response to
both sterile and infectious inflammatory insults (Chiang
et al., 2015; Zhang et al., 2016) as well as increased mortality
during polymicrobial sepsis (Chiang et al., 2017). Silencing
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of GPR18 (DRV2) on human macrophages also leads to a loss
in their ability to clear bacteria and apoptotic cells, two key
resolution responses, thereby underscoring the role of this
RvD2-GPR18 axis in restabilising tissue function following
an inflammatory insult (Chiang et al., 2015; 2017).
SPM as allosteric modulators and antagonists
In addition to activating cognate receptors, SPM also regulate
the activity of receptors for other endogenous mediators.
LXA4 was recently found to be an endogenous allosteric mod-
ulator of the cannabinoid CB1 receptor (Pamplona et al.,
2012). This SPM enhanced the affinity of anandamide at the
CB1 receptor potentiating its biological actions without com-
peting for the orthosteric binding site of the CB1 receptor and
altering endocannabinoidmetabolism (Figure 3). In addition,
LXA4 displayed protective actions against β-amyloid
(1–40)-induced spatial memory impairment, actions that
were CB1 receptor-dependent (Pamplona et al., 2012).
Some SPM also act as antagonists to receptors of pro-
inflammatory eicosanoids. RvE1,MaR1 and its further metab-
olite 22-OH-MaR1 are all competitive antagonists of BLT1
receptors (Figure 3) inhibiting the signalling and biological
actions of the potent leukocyte chemoattractant LTB4 (Arita
et al., 2005; El Kebir et al., 2012; Oh et al., 2012; Colas et al.,
2016). In human neutrophils, BLT1 antagonism enhances
neutrophil apoptosis (El Kebir et al., 2012). Of note, during
self-limiting infectious inflammation, MaR1 concentrations
reach a maximum early on in the course of the inflammatory
process, concomitant with a rise in LTB4 (Colas et al., 2016).
This suggests that, MaR1 production may play an important
role in antagonizing the actions of LTB4, thereby limiting
neutrophil recruitment. These results also indicate that dis-
ruptions in the biosynthesis of this mediator may lead to
Figure 3
Distinct interactions between SPM and GPCRs in controlling host responses. (A) Depicts the receptors activated by select pro-resolving mediators
and the target cells in which these receptors mediate the actions of their cognate SPM. (B,C) Depicts the receptors at which each SPM acts as a (B)
antagonists/partial agonist or (C) allosteric modulator.
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Table 1
Biological actions of SPM analogues
Analogue Biological action Dose Reference
Lipoxin analogues
15(R/S)-methyl-LXA4 Inhibits vascular permeability






(Takano et al., 1998)
(Mitchell et al., 2002)
16-phenoxy-LXA4 Inhibits neutrophil infiltration in
response to LTB4
240 nM (Takano et al., 1997)
15-epi,16-phenoxy-LXA4 Inhibits neutrophil infiltration in
response to LTB4
240 nM (Takano et al., 1997)
16-parafluoro-phenoxy-LXA4 Inhibits PMN infiltration 26 nM (Takano et al., 1998)




Tissue protection and reduced
neutrophil infiltration during
kidney ischaemia–reperfusion.














15 μg per mouse





(Leonard et al., 2002)
(Levy et al., 2002)
(Schottelius et al., 2002)
(Gewirtz et al., 2002)




into the tempo mandibular
joint following CFA administration
Reduces neutrophil recruitment in
response to zymosan
Promotes regeneration of




10 ng per mouse
100 ng per mouse
1 μg per site
(Norling et al., 2011)




Reduces DC expression of






100 μg per mouse (Hua et al., 2014)
Benzo-diacetylenic-
17R-RvD1-methyl ester
Shortens the resolution interval,
Ri, during E. coli peritonitis
Reduces ischaemia-reperfusion-
initiated second organ injury
100 ng per mouse
1 μg per mouse
(Orr et al., 2015)
continues
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delayed resolution of responses. Together, these findings
highlight the utility of SPM as templates for the development
of novel receptor modulators.
Harnessing SPM biology towards
resolution pharmacology
SPM display potent biological actions without the side effects
displayed by traditional anti-inflammatories. The reason for
this lack of unwanted side effects may be attributable to the
mechanisms activated by SPM, which are distinct from those
regulated by anti-inflammatories. Indeed, SPM do not
completely abolish the production and actions of molecules
and cells considered to be inflammatory. Instead, these
mediators reprogramme both the immune response and stro-
mal cells limiting the production of inflammatory molecules
and up-regulate the expression of protective mediators
(Mukherjee et al., 2004; Pamplona et al., 2012; Lee et al.,
2013; Miyata et al., 2013; Dalli et al., 2014; Herova et al.,
2015; Colby et al., 2016; Codagnone et al., 2018; de Oliveira
et al., 2017). This reprogramming of the immune system is
also linked to the apparent lack of immunosuppressive
action. Thus, prompted by these observations, several studies
have explored the potential of harnessing these actions to
control excessive inflammation characteristic of many
diseases that afflict modern societies (Takano et al., 1997;
Leonard et al., 2002; Mitchell et al., 2002; Guilford et al.,
2004).
From these efforts, several generations of analogues and
mimetics are now developed (see Table 1) with the aim of
obtaining molecules with enhanced pharmacokinetics and
pharmacodynamics that are also amenable to scaled-up
synthesis (Takano et al., 1997; Leonard et al., 2002; Mitchell
et al., 2002; Guilford et al., 2004). The first of these developed
was the lipoxin analogues that retain the biological actions of
their parent molecules but with enhanced stability. One of
these analogues, a benzo-LXA4, displays potent host protec-
tive actions that include the ability to regulate neutrophil
responses and promote tissue repair and regeneration in
periodontal disease (Van Dyke et al., 2015). These observa-
tions have now been extended to humans where the
protective actions of this analogue are being investigated in
the context of human periodontal disease (ClinicalTrials.
gov Identifier: NCT02342691). A later generation analogue
of RvE1 displays potent protective actions in dry eye
syndrome in humans. In a phase 2 trial, this RvE1 analogue
significantly reduced disease incidence, controlling dry eye-
related inflammation, findings that are under further investi-
gation in a phase 3 trial (Wire, 2009.).
Additionally, recent studies have demonstrated the
protective actions of analogues of RvD1 (Orr et al., 2015)
and RvE2 (Fukuda et al., 2016). The RvD1 analogues retain
Table 1
(Continued)
Analogue Biological action Dose Reference
E-series resolvin analogues
RX-10045 Substrate/inhibitor for efflux
transporters multidrug resistance-
associated protein, breast cancer-
resistant protein and
organic cation transporter-1





Reduction from baseline in
controlled adverse environment-
induced staining
of the central cornea
Improvement in human dry
eye disease symptoms,
including dryness, stinging,







(Cholkar et al., 2015)




Reduces the number of exudate
leukocytes in response to
Propionibacterium acnes infection
300 fg–3 ng per mouse (Fukuda et al., 2016)
β-cyclopropane
resolvin E2
Reduces the number of exudate
leukocytes in response to
P. acnes infection
300 fg–3 ng per mouse (Fukuda et al., 2016)
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the ability to activate GPR32 (DRV1) as well as the tissue pro-
tective actions of the parent SPM (Orr et al., 2015). Enhanced
biological actions are also displayed the cyclopropane conge-
ners of RvE2 (Fukuda et al., 2016), thereby supporting a role
for these analogues as novel therapeutics.
Conclusion
The appreciation that resolution of inflammation is an ac-
tive process and SPM are central in controlling both cellu-
lar trafficking and responses has opened up new and
exciting horizons for the development of new therapeutics.
Given that resolution pharmacology-based medicines will
harness endogenous reparative responses, it is anticipated
that they will be burdened with lower side effects since
they will not interfere with natural host immunity, poten-
tially also increasing patient compliance. Furthermore,
these findings shed new light on the roles of omega-3 es-
sential fatty acids in the control of acute inflammation.
The protective actions observed in many clinical studies
using these fatty acids are not simply due to the inhibition
of inflammatory eicosanoid formation by competing for
the biosynthetic enzymes. Indeed, these substrates are pre-
cursors to structurally unique molecules, the SPM, that
carry potent tissue protective actions. Thus, these media-
tors may represent novel markers to determine the
pharmacodynamics and pharmacokinetics of omega-3 sup-
plements and their ability to influence the host response
in both healthy people as well as patients with inflamma-
tory diseases. While the evidence in humans for the utility
of this approach is still being investigated, results from an-
imal and initial human experiments are encouraging (Dalli
et al., 2013; Arnardottir et al., 2016; Barden et al., 2016;
Markworth et al., 2016; Gobbetti et al., 2017). Therefore,
resolution-based therapeutics provide an exciting new para-
digm for personalized medicine where supplementation
can be utilized to maintain/boost endogenous SPM levels
to preserve tissue resolution tone and health. Whereas in
disease settings, SPM-based drugs may be useful in regulat-
ing host responses to both local and systemic inflamma-
tion. In this context, nanomedicines enriched in SPM or
their analogues/mimetics (Norling et al., 2011) may provide
a tractable system for targeted tissue delivery that can con-
trol both inflammation and promote tissue repair and re-
generation (Van Dyke et al., 2015). Hence, resolution
pharmacology could provide the basis for reprograming
host immunity in order to expedite microbial clearance,
limit collateral tissue damage and stimulate tissue
regeneration.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Harding
et al., 2018) and are permanently archived in the Concise
Guide to PHARMACOLOGY 2017/18 (Alexander et al.,
2017a,b,c,d).
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